Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
19.45
-0.05 (-0.26%)
At close: Dec 20, 2024, 4:00 PM
19.32
-0.13 (-0.67%)
After-hours: Dec 20, 2024, 4:24 PM EST
Arrowhead Pharmaceuticals Revenue
In the fiscal year ending September 30, 2024, Arrowhead Pharmaceuticals had annual revenue of $3.55M, down -98.52%.
Revenue (ttm)
$3.55M
Revenue Growth
-98.52%
P/S Ratio
n/a
Revenue / Employee
$5,831
Employees
609
Market Cap
2.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Select Medical Holdings | 6.97B |
| Surgery Partners | 2.99B |
| Amneal Pharmaceuticals | 2.68B |
| Concentra Group Holdings Parent | 1.88B |
| Privia Health Group | 1.72B |
| HUTCHMED (China) | 610.81M |
| Protagonist Therapeutics | 323.80M |
| Kymera Therapeutics | 87.56M |
ARWR News
- 1 day ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 10 days ago - Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases - Business Wire
- 18 days ago - Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Business Wire
- 19 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Business Wire
- 24 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results - Business Wire
- 25 days ago - Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire